YOLFTbeta
Lunai Bioworks Inc.

Lunai Bioworks Inc.

LNAI · NASDAQ · Healthcare / Biotechnology

0.1648USD-0.07 (-30.20%)

Price History

Full chart

Market Stats

Previous Close0.2361
Open0.229
Day Range0.141 – 0.23
52-Week Range1.21 – 13.28
Volume846.09K
Market Cap8.75M
P/E (TTM)0.00
Forward P/E0.00
EPS-61.52
Dividend Yield0.00%
Beta0.34
50-Day Avg2.33
200-Day Avg3.81

About

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. David H. Weinstein
  • Employees29
  • Headquarters2080 Century Park East, Los Angeles, CA, United States, 90067, USA
  • Websitehttps://www.lunaibioworks.com

Leadership

  • Mr. David H. WeinsteinCEO & Director · b. 1961
  • Mr. Nathen Fuentes CPAChief Financial Officer · b. 1983

Financials

Income Statement

Currency: USD2021-06-302022-06-302023-06-302024-06-302025-06-30
Total Revenue-0000
Cost of Revenue391.42K---129.09K
Gross Profit-391.42K-00-129.09K
Operating Expense23.01M-38.56M81.64M18.42M
Operating Income-23.40M-116.08M-38.56M-81.64M-18.55M
EBITDA-26.08M-112.94M-38.86M-85.87M-177.15M
Net Income-26.72M-113.43M-39.68M-88.43M-178.01M
R&D15.54M8.37M4.17M2.71M537.43K
Interest Expense379.61K372.84K706.96K2.43M725.68K

Balance Sheet

Currency: USD2021-06-302022-06-302023-06-302024-06-302025-06-30
Total Assets189.61M84.63M58.30M163.13M8.23M
Total Liabilities14.94M12.01M11.80M31.15M29.58M
Total Equity174.66M72.62M46.50M131.98M-21.35M
Cash20.66M9.17M1.87M220.47K92.70K
Total Debt7.37M7.02M5.59M3.79M10.17M
Net Debt-13.29M-2.16M3.72M3.57M10.08M

Cash Flow

Currency: USD2021-06-302022-06-302023-06-302024-06-302025-06-30
Operating Cash Flow-20.61M-15.73M-11.77M-10.97M-7.87M
Investing Cash Flow-48.89K-5.16K-29.77K-1.26M-500.00K
Financing Cash Flow32.60M4.25M4.52M10.52M8.38M
Capital Expenditure48.89K5.16K29.77K70.43K3
Free Cash Flow-20.66M-15.74M-11.80M-11.04M-7.87M
FCF to OCF100.24%100.03%100.25%100.64%100.00%

Earnings

Report DateMar 31, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016May 15, 2017Sep 29, 2017Nov 20, 2017Feb 9, 2018May 15, 2018Jun 30, 2018Oct 1, 2018Feb 13, 2019May 16, 2019Sep 30, 2019Nov 13, 2019Feb 10, 2020May 11, 2020Sep 23, 2020Nov 12, 2020Feb 16, 2021May 17, 2021Sep 24, 2021Nov 15, 2021Feb 14, 2022May 13, 2022Jun 30, 2022Sep 30, 2022Feb 27, 2023May 12, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Feb 19, 2025May 15, 2025Sep 29, 2025Nov 17, 2025Feb 17, 2026May 14, 2026Sep 25, 2026Oct 2, 2026
EPS Estimate----------------------------------------------
EPS Actual-10.50-2.94-3.54-1.74-6.34-6.66-7.71-0.03-0.02-0.02-0.08-0.12-10.82-0.14-0.50-0.130.18-0.09-0.04-0.03-0.09-0.05-0.06-0.09-0.36-0.20-0.13-0.12-136.19-11.18-1.70-0.08-29.14-11.38-5.50-43.20-11.87-22.11-0.040.01-7.200.13-0.08-0.10--
Surprise----------------------------------------------
Timing-----------------------------------------After-hoursAfter-hoursAfter-hours--

Key Statistics & Ratios

Market Cap8.75M
Enterprise Value8.37M
Trailing P/E0.00
Forward P/E0.00
Price / Sales417.84
Price / Book0.48
EPS-61.52
Book Value-2.14
Revenue (TTM)20.94K
Gross Profit (TTM)20.94K
EBITDA-9.77M
Profit Margin0.00%
Operating Margin-6815.30%
Return on Equity-325.46%
Return on Assets-9.65%
Shares Outstanding4.53M
Shares Float2.65M
Beta0.34
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
4.36%
Insiders
40.72%
Retail / Other
54.92%

Top Institutional Holders

  • Ground Swell Capital, LLC
    53.21K1.17%
  • Geode Capital Management, LLC
    182.24K0.50%
  • BlackRock Inc
    127.31K0.35%
  • Nine Masts Capital Limited
    102.43K0.28%
  • Citigroup Inc
    100.09K0.28%
  • Vanguard Capital Management, LLC
    96.50K0.27%
  • Virtu Financial LLC
    75.17K0.21%
  • Vanguard Fiduciary Trust Co
    69.14K0.19%
  • XTX Topco Ltd
    52.48K0.14%
  • Northern Trust Corp
    37.40K0.10%
  • State Street Corp
    35.73K0.10%
  • TWO SIGMA SECURITIES, LLC
    25.09K0.07%
  • Jump Financial LLC
    19.46K0.05%
  • Scientech Research LLC
    13.67K0.04%
  • The Goldman Sachs Group Inc
    12.08K0.03%
  • UBS Group AG
    11.44K0.03%
  • Tower Research Capital LLC
    4.70K0.01%

Top Fund Holders

  • Fidelity Extended Market Index
    17.83K0.39%
  • Fidelity Total Market Index
    1.90K0.04%
  • Fidelity Series Total Market Index
    1.75K0.04%

Stock Splits

  • May 22, 20261:8
  • Sep 30, 20251:10